Nicoletti Alberto, Maurice James B, Thorburn Douglas
Sheila Sherlock Liver Centre and UCL Institute for Liver and Digestive Health, Royal Free London NHS Foundation Trust, London, UK.
Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Frontline Gastroenterol. 2020 Mar 2;12(1):62-66. doi: 10.1136/flgastro-2019-101343. eCollection 2021.
New British Society of Gastroenterology/UK-PSC guidelines have recently discussed the current state-of-the-art on primary sclerosing cholangitis and outlined key elements for the management of this disease. The current lack of effective pharmacological treatments to prevent progression of liver fibrosis to cirrhosis limits our ability to modify the natural history of the disease. However, a personalised approach and structured follow-up could allow earlier diagnosis and management of complications and favour access to liver transplantation, which remains the only available treatment. Our commentary overviews the updates and summarises the key recommendations of the recent guidelines for the management of primary sclerosing cholangitis.
英国胃肠病学会/英国原发性硬化性胆管炎指南最近讨论了原发性硬化性胆管炎的当前技术水平，并概述了该疾病管理的关键要素。目前缺乏有效的药物治疗来预防肝纤维化进展为肝硬化，这限制了我们改变该疾病自然病程的能力。然而，个性化方法和结构化随访可以实现并发症的早期诊断和管理，并有助于获得肝移植，而肝移植仍然是唯一可用的治疗方法。我们的评论概述了这些更新内容，并总结了最近原发性硬化性胆管炎管理指南的关键建议。
